Trial Profile
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Seviteronel (Primary)
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms CLARITY; CLARITY-1
- Sponsors Innocrin Pharmaceuticals
- 31 Jan 2019 Status changed from active, no longer recruiting to completed.
- 06 Dec 2018 Planned End Date changed from 1 Dec 2018 to 1 May 2019.
- 06 Dec 2018 Planned primary completion date changed from 1 Dec 2018 to 1 May 2019.